From: Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer
In All Patients | |||||
---|---|---|---|---|---|
 | No. of patients | No. of deaths | HR | 95% CI | P |
Performance status OMS | 167 | Â | Â | Â | Â |
 0–1 | 134 | 91 | 1 |  |  |
  ≥ 2 | 33 | 30 | 2.191 | 1.413 to 3.396 | 0.0005 |
Stage | 167 | Â | Â | Â | Â |
 Local/Loco-regional | 84 | 48 | 1 |  |  |
 Advanced | 83 | 73 | 2.558 | 1.722 to 3.802 | <.0001 |
CD4+ T lymphocytes | 167 | Â | Â | Â | Â |
  ≥ 500 /μl | 120 | 80 | 1 |  |  |
  < 500 /μl | 47 | 41 | 1.422 | 0.971 to 2.083 | 0.0704 |
In patients with local/loco-regional NSCLC | |||||
 | No. of patients | No. of deaths | HR | 95% CI | P |
Performance status OMS | 84 | Â | Â | Â | Â |
 0–1 | 78 | 43 | 1 |  |  |
  ≥ 2 | 6 | 5 | 1.788 | 0.687 to 4.649 | 0.2335 |
CD4+ T lymphocytes | 84 | Â | Â | Â | Â |
  ≥ 500 /μl | 64 | 33 | 1 |  |  |
  < 500 /μl | 20 | 15 | 2.028 | 1.065 to 3.817 | 0.0288 |
In Advanced NSCLC | |||||
 | No. of patients | No. of deaths | HR | 95% CI | P |
Performance status OMS | 83 | Â | Â | Â | Â |
 0–1 | 56 | 48 | 1 |  |  |
  ≥ 2 | 27 | 25 | 2.270 | 1.354 to 3.806 | 0.0019 |
CD4+ T lymphocytes | 83 | Â | Â | Â | Â |
  ≥ 500 /μl | 56 | 47 | 1 |  |  |
  < 500 /μl | 27 | 26 | 1.198 | 0.737 to 1.946 | 0.4668 |